Search Results - "Clement, C.M"

  • Showing 1 - 13 results of 13
Refine Results
  1. 1
  2. 2
  3. 3

    Minimally important differences in oral health-related quality of life after fixed orthodontic treatment: a prospective cohort study by LAU, Clement C M, Savoldi, Fabio, Yang, Yanqi, Hägg, Urban, McGrath, Colman P, Gu, Min

    Published in European journal of orthodontics (31-05-2023)
    “…Summary Background The minimally important difference (MID, the smallest difference that patients perceive as beneficial) has been proposed to assess whether…”
    Get full text
    Journal Article
  4. 4

    Lipopolysaccharide-induced nigral inflammation leads to increased IL-1β tissue content and expression of astrocytic glial cell line-derived neurotrophic factor by Iravani, Mahmoud M., Sadeghian, Mona, Leung, Clement C.M., Jenner, Peter, Rose, Sarah

    Published in Neuroscience letters (29-02-2012)
    “…► At 24h following nigral LPS, IL-1β but TNF-α was insignificantly release. ► LPS treatment led to astrocytic but not microglial expression of GDNF. ►…”
    Get full text
    Journal Article
  5. 5

    Endovenous laser ablation versus mechanochemical ablation with ClariVein(®) in the management of superficial venous insufficiency (LAMA trial): study protocol for a randomised controlled trial by Leung, Clement C M, Carradice, Daniel, Wallace, Tom, Chetter, Ian C

    “…Endovenous thermal techniques, such as endovenous laser ablation (EVLA), are the recommended treatment for truncal varicose veins. However, a disadvantage of…”
    Get full text
    Journal Article
  6. 6

    The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation by Iravani, Mahmoud M., Leung, Clement C. M., Sadeghian, Mona, Haddon, Claire O., Rose, Sarah, Jenner, Peter

    Published in The European journal of neuroscience (01-07-2005)
    “…Sustained reactive microgliosis may contribute to the progressive degeneration of nigral dopaminergic neurons in Parkinson's disease (PD), in…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response by Iravani, Mahmoud M., Sadeghian, Mona, Leung, Clement C.M., Tel, Banu C., Rose, Sarah, Schapira, Anthony H., Jenner, Peter

    Published in Experimental neurology (01-08-2008)
    “…The D2/D3 dopamine receptor agonist pramipexole, protects against toxin-induced dopaminergic neuronal destruction but its mechanism of action is unknown…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13